This effect is unlikely to be caused by infusion with low-dose cisplatin (6 mg/m2) that preceded radiotherapy fractions, since cisplatin has been shown to stimulate antitumor immunity, in particular by the induction of tumor-specific CD8+ T cells, by promoting infiltration of inflammatory APCs harboring T-cell co-stimulatory ligands into the tumor, and by improving cure rates when combined with long peptide vaccines.26,27. This evidence concerns the gene CD8A and neoplasm.